APTO News and Press, Aptose Biosciences Inc. From 08/03/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President a...

Aptose Biosciences has been on a roller coaster of a ride in the past 3 years, plummeting to a low of $0.90 in December of 2016 and reaching a high of $4.20 in June of 2018. For those who don't know, Aptose is a small-cap biotech company that trades on the TSX (Ticker Symbol: APS) and on the N...

SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of...

 – CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML  –  – APTO-253 MYC inhibitor being developed for the treatment of AML and MDS   – SAN DI...

– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing ...

Play Video It’s no secret that the healthcare systems in Canada and the US have for years been compared to one another and, as neighboring countries, it’s impossible not to pin the two against each ot...

SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today ann...

SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Jotin Marango, M.D., Ph.D., to ...

SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 10,000,000 common shares at a price to t...